% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/ugt.R
\name{basic_ugt_inhibition_risk}
\alias{basic_ugt_inhibition_risk}
\title{UGT inhibition risk}
\usage{
basic_ugt_inhibition_risk(perp, ugt_inh)
}
\arguments{
\item{perp}{The perpetrator object.}

\item{ugt_inh}{UGT inhibition data as data frame, The following fields are
expected:
\itemize{
\item 'name' The name of the perpetrator compound.
\item 'ugt' The UGT enzyme as (upper case) character.
\item 'ic50' The \eqn{IC_{50}} in \eqn{\mu M} as numeric.
\item 'source' Optional source information as character.
}}
}
\value{
A markdown-formatted table.
}
\description{
This function evaluates the clinical risk for reversible inhibition of UGT
enzymes according to the relevant \href{https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m12-guideline-drug-interaction-studies-step-5_en.pdf}{regulatory guideline}.
}
\details{
This function assumes that the UGT inhibition data is provided as
\eqn{IC_{50}}. According to
\href{https://doi.org/10.1016/0006-2952(73)90196-2}{Cheng, Prusoff 1973}),
\eqn{K_i} can be assumed to be \eqn{IC_{50}/2} at the experimental conditions
commonly used in the in vitro inhibition studies where substrate
concentrations are close to \eqn{K_M}.

The relevant metric for basic modeling of the UGT inhibition risk is
\eqn{R=C_{max,ss,u}/K_{i,u}}

Refer to Section 2.1.2.1 of the \href{https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m12-guideline-drug-interaction-studies-step-5_en.pdf}{ICH M12 guidance document})
for details.

\eqn{R>0.02} are considered to indicate a potential UGT inhibition risk.
}
\examples{
basic_ugt_inhibition_risk(examplinib_parent, examplinib_ugt_inhibition_data)
}
\seealso{
\code{\link[=key_concentrations]{key_concentrations()}}

\code{\link[=basic_ugt_inhibition_risk_table]{basic_ugt_inhibition_risk_table()}}

\code{\link[=read_ugt_inhibitor_data]{read_ugt_inhibitor_data()}}
}
